

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8065471

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the THE ASSIGNEE PREVIOUSLY RECORDED SHOULD BE UPDATED TO RESEARCH FOUNDATION TO CURE AIDS, INC. previously recorded on Reel 060842 Frame 0078. Assignor(s) hereby confirms the ASSIGNEE.
SEQUENCE:	1

CONVEYING PARTY DATA

Name	Execution Date
KAMBIZ SHEKDAR	05/18/2022

RECEIVING PARTY DATA

Name:	RESEARCH FOUNDATION TO CURE AIDS, INC.
Street Address:	40 REMSEN STREET, #4
City:	BROOKLYN
State/Country:	NEW YORK
Postal Code:	11201

PROPERTY NUMBERS Total: 3

Property Type	Number
Application Number:	14777490
Application Number:	16855512
Patent Number:	11680265

CORRESPONDENCE DATA

Fax Number: (650)494-0792
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6508135600
Email: hbirdwell@mofocom
Correspondent Name: STEPHEN FRAUSTO
Address Line 1: 755 PAGE MILL ROAD
Address Line 4: PALO ALTO, CALIFORNIA 94304-1018

ATTORNEY DOCKET NUMBER:	87389-28000.00
NAME OF SUBMITTER:	STEPHEN D. FRAUSTO
SIGNATURE:	/Stephen Frausto/
DATE SIGNED:	07/19/2023
Total Attachments: 5	

source=87389-28000_00_Previous_Cover_Sheet#page1.tif
source=87389-28000_00_Previous_Cover_Sheet#page2.tif
source=87389-28000_00_Previous_Cover_Sheet#page3.tif
source=87389-28000_00_Previous_Cover_Sheet#page4.tif
source=87389-28000_00_Previous_Cover_Sheet#page5.tif

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KAMBIZ SHEKDAR	05/18/2022
RECEIVING PARTY DATA	
Name:	RESEARCH FOUNDATION TO CURE AIDS, <u>Inc.</u>
Street Address:	40 REMSEN STREET, #4
City:	BROOKLYN
State/Country:	NEW YORK
Postal Code:	11201
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	61801822
Application Number:	61867522
Patent Number:	10669547
Application Number:	16858512
CORRESPONDENCE DATA	
Fax Number:	(650)494-0792
Phone:	(650) 813-6496
Email:	RLang@mofa.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	STEPHEN FRAUSTO
Address Line 1:	MORRISON & FOERSTER LLP
Address Line 2:	755 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304-1018
ATTORNEY DOCKET NUMBER:	87389-28000_00
NAME OF SUBMITTER:	STEPHEN FRAUSTO
Signature:	/Stephen Frausto/
Date:	08/18/2022

Total Attachments: 3

source=87389-28000_00_Assignment#page1.tif

source=87389-28000_00_Assignment#page2.tif

source=87389-28000_00_Assignment#page3.tif

RECEIPT INFORMATION

EPAS ID: PAT7492298

Receipt Date: 08/18/2022

ASSIGNMENT

This assignment is by:

1 Kambiz Shekdar
40 Remsen Street, #4
Brooklyn, NY 11201
United States of America

(referred to in this Assignment as "Assignor"), which is the sole and exclusive owner, by assignment, of the patents and patent applications identified in **Schedule A**, appended hereto.

This Assignment is to:

Assignee: Research Foundation to Cure AIDS
Address: 40 Remsen Street, #4
Brooklyn, NY 11201
United States of America
A juristic entity duly organized under and pursuant to the laws of: New York

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patents and patent applications, and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions (as covered by the patents and patent applications identified in **Schedule A**), application for letters patent, any and all non-provisionals, divisions, continuations, and continuations-in-part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.

2. Assignor represents, warrants and covenants (a) that, at the time of execution and delivery of this agreement, Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same are unencumbered and that Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement, or (b) that Assignor solely and lawfully owned Assignor's entire right, title and interest in and to said inventions arising from Assignor's inventorship thereof and said application for letters patent, and that the same were unencumbered and that Assignor previously sold, assigned, transferred and set over, to Assignee, its successors, legal representatives and assigns, or to a predecessor in interest of Assignee, Assignor's entire right, title and interest in and to said inventions and said applications for letters patent.

3. Assignor shall promptly sign, execute, and deliver to Assignee all papers, instruments, affidavits, and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said application for letters patent; (b) any non-provisional, division, continuation, or continuation-in-part claiming priority thereto or the benefit thereof, or any substitution of any such application, or (c) any letters patent or patents for said inventions in any country or jurisdiction, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination, or other post-grant proceeding. For purposes of this paragraph, "procurement, maintenance, enforcement, defense" shall include, without limitation, any preparation, prosecution, pre-grant proceeding, and post-grant proceeding, whether before a patent office or other administrative body or judicial body with jurisdiction therefor.

4. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patents to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. Assignor hereby grants attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).


ASSIGNOR(s):

Date: May 18, 2022 Signature:


Kambiz Shekdar

ASSIGNEE:

Date: May 19 2022 Signature:


Name: KAMBIZ SHEKDAR
Title: PRESIDENT
Company: Research Foundation to Cure AIDS

SCHEDULE A

No.	Country	Title	Application No. App. Date	Patent/ Pub. No.
1.	United States of America	GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR HIV TREATMENT	61/801,822 3/15/2013	
2.	United States of America	COMPOSITIONS OF MODIFIED STEM CELLS AND METHODS OF USE FOR HIV THERAPY	61/867,522 8/19/2013	
3.	United States of America	GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT	14/777,490 3/13/2014	10,669,547
4.	United States of America	GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT	16/858,512 4/24/2020	2020-0407727
5.	Patent Cooperation Treaty	GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT	PCT/US2014/026787 3/13/2014	2014/151994
6.	Brazil	GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT	112015023405-4 3/13/2014	1120150234054
7.	European Patent Office	GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT	14770615.4 3/13/2014	2970971
8.	South Africa	GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT	2015/06573 3/13/2014	2015/06573
9.	Switzerland	GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT	14770615.4 3/13/2014	2970971
10.	Germany	GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT	14770615.4 3/13/2014	602014069712.7
11.	France	GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT	14770615.4 3/13/2014	2970971
12.	United Kingdom	GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT	14770615.4 3/13/2014	2970971